Parkinson’s is characterized by the accumulation of misfolded alpha-synuclein proteins in the brain. These proteins are a key factor in the development of Parkinson’s, as they clump together and become toxic, leading to a decline in dopamine-producing cells.

Due to its vital role in Parkinson’s, alpha-synuclein has been a major target for drug development. Several experimental therapies aimed at targeting this protein are currently in ongoing clinical trials.

This past week, two pharmaceutical companies reported on results from two Phase II clinical trials aimed at slowing the progression of Parkinson’s by targeting alpha-synuclein.

• The UCB-Novartis ORCHESTRA trial of minzasolmin was unable to show any significant benefit in slowing down the progression of Parkinson’s. As a result, the companies have decided to end further development of this drug.
• The Roche PADOVA trial of prasinezumab did not reach its primary endpoint. However, the results indicated some potential benefits, prompting Roche to explore the data and determine the next steps.

While these outcomes can be disheartening for our community, it’s important to remember that drug development is a complex process. Continued research and innovation as well as ongoing discovery of the underlying biological processes that are associated with the development and progression of Parkinson’s are essential to finding effective treatments for Parkinson’s.

While Parkinson Canada was not involved in these trials, we continue to be committed to funding key research aimed at better understanding Parkinson’s.

For more information on these trials, you can read the full press release here.